Reply: Lung Cancer Susceptibility, Ethnicity, and the Benefits of Computed Tomography Screening by Ruparel, M & Navani, N
Response	to	comment	by	Hopkins	et	al: 
Lung	cancer	susceptibility,	ethnicity	and	the	benefits	of	CT	screening 
	 
Following	our	editorial: 
Fulfilling	the	Dream:	Toward	Reducing	Inequalities	in	Lung	Cancer	Screening.	Am	J	Respir	Crit	Care	
Med	2015;	192:	125-127	PubMed	. 
	 
Authors: 
Mamta	Ruparel1,	Neal	Navani1,2. 
	 
Affiliations: 
1Lungs	for	Living	Research	Centre,	UCL	Respiratory,	University	College	London,	UK 
2Department	of	Thoracic	Medicine,	University	College	Hospital,	London,	UK 
	 
Correspondence	to: 
Dr	Neal	Navani 
Department	of	Thoracic	Medicine,	University	College	Hospital,	250	Euston	Road,	London	NW1	2PG,	
United	Kingdom 
n.navani@ucl.ac.uk 
	 
Author	contribution: 
Both	authors	(MR	&	NN	contributed	to	the	conception	and	design;	drafting,	review	and	final	approval	of	
this	manuscript). 
	 
Funding:	The	authors	have	no	disclosures	to	make	in	relation	to	this	manuscript. 
	
 
Response	to	comment:		Lung	cancer	susceptibility	and	mortality	benefit	in	lung	cancer	screening		(434	
words) 
M	Ruparel	&	N	Navani 
	 
We	thank	Hopkins	and	colleagues	for	their	 interest	 in	our	editorial(1).	We	acknowledge	the	important	
studies	cited	which	suggest	that	African-Americans	have	an	increased	susceptibility	to	cigarette	smoke	
and	are	therefore	at	higher	risk	of	developing	COPD	and	lung	cancer	than	matched	Caucasian	individuals	
(even	after	considering	the	impact	of	other	related	factors)	(Hopkins	et	al,	this	issue). 
	 
We	would	however	like	to	highlight	the	difference	between	lung	cancer	detection	rate	and	reduction	in	
mortality.	While	 both	 are	 related	 to	 lung	 cancer	 risk	 and	 incidence,	 the	 latter	 also	 addresses	 factors	
affecting	competing	mortality.	The	paper	by	Tanner	and	colleagues	that	we	referred	to,	reported	a	more	
pronounced	mortality	benefit	with	LDCT	screening	compared	with	chest	x-ray	 in	Black	compared	with	
non-Black	NLST	participants(2).	This	suggests	an	observed	effect	of	LDCT	screening	in	Black	participants	
over	and	above	that	explained	by	the	increase	in	risk	and	incidence	alone	in	this	ethnic	group. 
	 
As	 well	 as	 ethnicity,	 other	 factors	 appear	 to	 influence	 lung	 cancer	 susceptibility.	 Gender	 is	 another	
important	demographic	that	influences	lung	cancer	risk	and	certainly	it	has	been	suggested	that	the	cost	
effectiveness	 of	 lung	 cancer	 screening	 is	 far	 higher	 in	women	 compared	with	men	 (ICER	 $46,000	 vs.	
$147,000	(3)).		Furthermore,	 as	well	 as	 COPD,	 other	 comorbidities	 also	 increase	 susceptibility	 to	 lung	
cancer	 through	 varying	mechanisms.	 Certainly,	 HIV	 and	 idiopathic	 pulmonary	 fibrosis	 have	 also	 been	
associated	with	a	higher	risk	of	lung	cancer	even	after	accounting	for	smoking	history(4,	5). 
	 
Another	 interesting	 observation	 is	 that	 interval	 cancers	 in	 the	 NELSON	 study	 were	 associated	 with	
increased	 age,	 though	 not	 smoking	 status(6).	 Apart	 from	 this	 study,	 very	 little	 is	 known	 about	 the	
relative	 importance	 of	 other	 factors	 influencing	 interval	 cancer	 incidence	 with	 LDCT	 screening	 and	
whether	such	occurrences	may	be	predicted	by	evaluating	risk	 in	screened	individuals.	 If	this	were	so,	
screening	intervals	could	be	tailored	individually	by	risk. 
	 
The	 relationship	 between	 individual	 lung	 cancer	 risk,	 lung	 cancer	 detection,	 survival	 benefit	 of	 the	
screened	 population	 and	 cost-effectiveness	 of	 lung	 cancer	 screening	 is	 complex.	 The	 current	 USPSTF	
criteria(7)	for	screening	eligibility	are	reasonable	at	this	time,	but	are	likely	to	be	adapted	in	the	future,	
given	the	growing	evidence	base	that	will	in	due	course	inform	the	medical	communities	on	how	best	to	
optimise	 the	 harms	 and	 benefits	 of	 lung	 cancer	 screening	 in	 individuals	 with	 varying	 risk	 profiles.	
Screening	 may	 be	 appropriate	 at	 alternative	 age	 and	 risk	 thresholds,	 or	 at	 more	 or	 less	 frequent	
intervals	 in	 certain	 groups.	 Lung	 cancer	 risk	 and	 detection	 rate	 both	 need	 to	 be	 balanced	 with	
competing	mortality	 in	 order	maintain	 or	 exceed	 the	 sensitivity	 and	mortality	 benefit	with	 screening	
seen	in	NLST. 
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